Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03363893 · ClinicalTrials.gov registry record · Phase 1
Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies
A Phase 1 study, sponsored by Carrick Therapeutics Limited.
- Completed
- Registry status
- Phase 1
- Development phase
- 124
- Enrollment target
NCT03363893: Completed Phase 1 study, sponsored by Carrick Therapeutics Limited.
NCT03363893 is a Phase 1 study that has completed, run by Carrick Therapeutics Limited. The registered enrollment target is 124 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (107% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03363893, a Phase 1 study, has completed, sponsored by Carrick Therapeutics Limited.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 124 participants
- Enrollment target
Study Summary
This is a modular, Phase I/II, multicentre study to investigate CT7001 monotherapy in advanced solid malignancies and to further investigate CT7001 as monotherapy or in combination with standard therapy in specific participant groups with Triple Negative Breast Cancer (TNBC), Castrate Resistant Prostate Cancer (CRPC) and in combination with fulvestrant for patients with hormone receptor-positive (HR+ve) / human epidermal growth factor-2 negative (HER2-ve) breast cancer.
Primary Outcome
Treatment-emergent adverse events (TEAEs) are defined as those AEs which occur from Cycle 0 Day 1/Cycle 1 Day 1 of the study module to 28 days after the last dose of CT7001 in a module. Results reported below for Participants with one or more related TEAEs.
Interventions
- DRUG Fulvestrant
- DRUG CT7001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2017-11-14 |
| Est. Completion | 2022-12-15 |
| Phase | Phase 1 |
What the finished NCT03363893 record still lists
NCT03363893 is an interventional study that assigns participants to a tested intervention. The registered 124 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (107% higher).
The record links to 0 conditions, and to 2 interventions - of which Fulvestrant is the first listed.
NCT03363893 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03363893 about?
NCT03363893 is a clinical study titled "Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies". This is a modular, Phase I/II, multicentre study to investigate CT7001 monotherapy in advanced solid malignancies and to further investigate CT7001 as monotherapy or in combination with standard therapy in specific participant groups with Triple Negative Breast Cancer (TNBC), Castrate Resistant Pros...
What is the current status of trial NCT03363893?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 124 participants. The study started on 2017-11-14. Estimated completion is 2022-12-15.
What interventions are being tested in trial NCT03363893?
The interventions under investigation include: Fulvestrant (DRUG), CT7001 (DRUG).
Who is sponsoring clinical trial NCT03363893?
This trial is sponsored by Carrick Therapeutics Limited, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03363893's enrollment target sits among peer trials
124 471st of 2000 higher than 1,526 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523014 · 124 participants · Phase 2
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
- NCT02670707 · 124 participants · Phase 3
Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)
- NCT02830724 · 124 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
- NCT04748809 · 124 participants · NA
Effect of Anti-inflammatory Diet in Rheumatoid Arthritis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI